Promising prostate cancer combo study halted before results

NCT ID NCT01995058

First seen Jan 10, 2026 · Last updated May 03, 2026 · Updated 19 times

Summary

This study tested a combination of two drugs, cabozantinib and abiraterone, in men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The goal was to see if the combination could delay cancer growth or death. However, the study was stopped early by the sponsor for business reasons, so no results on effectiveness were collected.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Study site

    Scottsdale, Arizona, 85258, United States

  • Study site

    Sedona, Arizona, 86336, United States

  • Study site

    Tucson, Arizona, 85710, United States

  • Study site

    Oxnard, California, 93030, United States

  • Study site

    San Diego, California, 92108, United States

  • Study site

    Aurora, Colorado, 80012, United States

  • Study site

    Aurora, Colorado, 80045, United States

  • Study site

    Athens, Georgia, 30607, United States

  • Study site

    Atlanta, Georgia, 30318, United States

  • Study site

    Peoria, Illinois, 61615, United States

  • Study site

    Wichita, Kansas, 67214, United States

  • Study site

    Las Vegas, Nevada, 89148, United States

  • Study site

    Raleigh, North Carolina, 27607, United States

  • Study site

    Tualatin, Oregon, 97062, United States

  • Study site

    Charleston, South Carolina, 29414, United States

  • Study site

    Greenville, South Carolina, 29605, United States

  • Study site

    Myrtle Beach, South Carolina, 29572, United States

  • Study site

    Dallas, Texas, 75246, United States

  • Study site

    Houston, Texas, 77024, United States

  • Study site

    Salt Lake City, Utah, 84112, United States

Conditions

Explore the condition pages connected to this study.